ATE459339T1 - Künstliche antigen-spezifischen zellen und zugehörige verfahren - Google Patents

Künstliche antigen-spezifischen zellen und zugehörige verfahren

Info

Publication number
ATE459339T1
ATE459339T1 AT99955116T AT99955116T ATE459339T1 AT E459339 T1 ATE459339 T1 AT E459339T1 AT 99955116 T AT99955116 T AT 99955116T AT 99955116 T AT99955116 T AT 99955116T AT E459339 T1 ATE459339 T1 AT E459339T1
Authority
AT
Austria
Prior art keywords
artificial antigen
cells
antigen presenting
molecules
presenting cells
Prior art date
Application number
AT99955116T
Other languages
English (en)
Inventor
Salvatore Albani
Original Assignee
Androclus Technologies S R L I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Androclus Technologies S R L I filed Critical Androclus Technologies S R L I
Application granted granted Critical
Publication of ATE459339T1 publication Critical patent/ATE459339T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0006—Modification of the membrane of cells, e.g. cell decoration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
AT99955116T 1998-10-20 1999-10-19 Künstliche antigen-spezifischen zellen und zugehörige verfahren ATE459339T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10501898P 1998-10-20 1998-10-20
PCT/US1999/024666 WO2000023053A2 (en) 1998-10-20 1999-10-19 Artificial antigen-specific cells and related methods

Publications (1)

Publication Number Publication Date
ATE459339T1 true ATE459339T1 (de) 2010-03-15

Family

ID=22303617

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99955116T ATE459339T1 (de) 1998-10-20 1999-10-19 Künstliche antigen-spezifischen zellen und zugehörige verfahren

Country Status (10)

Country Link
US (1) US7022483B1 (de)
EP (1) EP1123086B1 (de)
JP (1) JP2002527467A (de)
AT (1) ATE459339T1 (de)
AU (2) AU774442B2 (de)
CA (1) CA2345277C (de)
DE (1) DE69942100D1 (de)
DK (1) DK1123086T3 (de)
HK (1) HK1041433A1 (de)
WO (1) WO2000023053A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521202B2 (en) 1999-12-17 2009-04-21 The Board Of Regents Of The University Of Oklahoma Method and apparatus for the production of soluble MHC antigens and uses thereof
AU2001265346A1 (en) * 2000-06-02 2001-12-17 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
CA2433194C (en) 2000-10-10 2012-04-03 The Board Of Regents Of The University Of Oklahoma Comparative ligand mapping from mhc positive cells
US20070026433A1 (en) 2001-03-09 2007-02-01 Hildebrand William H Epitope testing using soluble HLA
WO2002056908A2 (en) * 2001-01-16 2002-07-25 Hildebrand William H Artificial antigen-presenting cells
AU2002240818C1 (en) * 2001-03-14 2008-11-06 Agilent Technologies, Inc. MHC molecule constructs and their uses for diagnosis and therapy
US20050130886A1 (en) * 2001-05-14 2005-06-16 Jan Holmgren Methods for promoting antigen presentation and modulating immune responses using cholera toxin and its b subunit
EP2687593A1 (de) 2001-05-15 2014-01-22 Ortho-McNeil Pharmaceutical, Inc. Ex-vivo-Priming zur Erzeugung zytotoxischer T-Lymphozyten, die für Nicht-Tumorantigene spezifisch sind, zur Behandlung von Autoimmunerkrankung und Allergie
US7902121B2 (en) * 2001-07-02 2011-03-08 The Board Of Trustees Of The Leland Stanford Junior University MHC-antigen arrays for detection and characterization of immune responses
EP1473564A4 (de) * 2001-09-18 2008-12-10 Greenpeptide Co Ltd Verfahren zum nachweis von zellimmunität und dessen anwendung auf arzneistoffe
JP2005532981A (ja) 2001-09-25 2005-11-04 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 免疫媒介疾患における病原性免疫応答を調節するためのエピトープ特異的およびサイトカイン／抗サイトカイン併用免疫治療法
FR2830940B1 (fr) * 2001-10-17 2007-06-15 Commissariat Energie Atomique Procede de selection de ligands d'hla-dp4 et ses applications
DK1623017T3 (da) * 2003-05-08 2011-01-10 Life Technologies Corp Frembringelse og isolering af antigenspecifikke T-celler
GB0318096D0 (en) * 2003-08-01 2003-09-03 Queen Mary & Westfield College Vaccine
US8158411B2 (en) 2006-08-21 2012-04-17 Samsung Electronics Co., Ltd. Method of separating microorganism using nonplanar solid substrate and device for separating microorganism using the same
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
WO2009003493A2 (en) 2007-07-03 2009-01-08 Dako Denmark A/S Mhc multimers, methods for their generation, labeling and use
EP2197908A2 (de) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc-multimere in tuberkulose-diagnostika, -impfstoff und therapeutika
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
US20120034156A1 (en) * 2010-08-03 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010061919A1 (ja) 2008-11-28 2010-06-03 日油株式会社 Ｓａｒｓコロナウイルスの細胞傷害性ｔ細胞エピトープペプチド及びその用途
SI2869848T1 (sl) 2012-07-04 2017-01-31 F. Hoffmann-La Roche Ag Kovalentno vezani konjugati antigen-protitelo
MX373856B (es) 2014-01-03 2020-03-25 Hoffmann La Roche Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos.
ES2895752T3 (es) 2014-01-03 2022-02-22 Hoffmann La Roche Anticuerpos biespecíficos anti-hapteno/anti-receptor de la barrera hematoencefálica, complejos de los mismos y su uso como lanzaderas a través de la barrera hematoencefálica
MX373017B (es) * 2014-01-03 2020-04-28 Hoffmann La Roche Conjugados de toxina polipeptidica-anticuerpo unidos covalentemente.
JP6508873B2 (ja) * 2014-01-20 2019-05-08 国立大学法人富山大学 抗原特異的ｔ細胞受容体の取得方法
WO2015148960A1 (en) 2014-03-28 2015-10-01 The Board Of Regents Of The University Of Oklahoma Compositions comprising soluble hla/m. tuberculosis-specific ligand complexes and methods of production and use thereof
WO2017147508A1 (en) * 2016-02-26 2017-08-31 Sri International Identification and isolation of antibodies from white blood cells
EP3458058B1 (de) * 2016-05-18 2024-07-03 Singapore Health Services Pte Ltd Pharmazeutische zusammensetzung und deren verwendung bei der behandlung von autoimmunerkrankungen
WO2017216768A1 (en) 2016-06-16 2017-12-21 Association For The Advancement Of Tissue Engineering And Cell Based Technologies And Therapies - A4Tec Dendrimer-derived artificial antigen, methods and uses thereof
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
EP3509629A1 (de) * 2016-09-06 2019-07-17 H. Hoffnabb-La Roche Ag Mhc-gebundene peptid-arrays und verfahren zur verwendung davon
EP3898666A2 (de) 2018-12-17 2021-10-27 Immudex ApS Panel mit borrelia-mhc-multimeren
US20220226448A1 (en) * 2019-05-22 2022-07-21 Baylor Research Institute One-step artificial antigen presenting cell-based vaccines
WO2021216738A2 (en) * 2020-04-21 2021-10-28 Intima Bioscience, Inc. Compositions and methods of generating an immune response
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1979000160A1 (en) 1977-09-28 1979-04-05 Nat Res Dev Improvements in or relating to immunological preparations
DE3063736D1 (en) 1979-03-27 1983-07-21 Nat Res Dev Improvements in or relating to immunological preparations
US4885172A (en) 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5194425A (en) * 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
US5468481A (en) 1988-06-23 1995-11-21 Amergen, Inc. MHC class II-peptide conjugates useful in ameliorating autoimmunity
FR2636339B1 (fr) 1988-09-09 1992-07-17 Auge Pier Gel aqueux a base d'acide hyaluronique et d'acide desoxyribonucleique utilisable en cosmetique, et procede de preparation
DE69032841T2 (de) 1989-01-23 1999-05-12 Chiron Corp., Emeryville, Calif. Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung
WO1990010385A1 (en) * 1989-03-15 1990-09-20 Tykocinski Mark L Cd8-based pharmaceuticals
US5216132A (en) 1990-01-12 1993-06-01 Protein Design Labs, Inc. Soluble t-cell antigen receptor chimeric antigens
US5283058A (en) 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
US5734023A (en) 1991-11-19 1998-03-31 Anergen Inc. MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
AU671971B2 (en) 1991-11-29 1996-09-19 Chiron Corporation Anti-cancer immunotherapeutic vector constructs
DE69332485T2 (de) 1992-08-11 2003-11-13 The President And Fellows Of Harvard College, Cambridge Immunmodulierende peptide
GB9320597D0 (en) 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
US5763585A (en) 1993-10-13 1998-06-09 Anergen, Inc. Method of making MHC-peptide complexes using metal chelate affinity chromatography
WO1995011255A1 (en) 1993-10-19 1995-04-27 Ajinomoto Co., Inc. Peptide capable of inducing immune response against hiv and aids preventive or remedy containing the peptide
US5891689A (en) 1994-04-12 1999-04-06 Innovir Laboratories, Inc. Heme-bearing microparticles for targeted delivery of drugs
US5773570A (en) 1994-05-20 1998-06-30 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
US5595881A (en) 1994-08-09 1997-01-21 Anergen, Inc. Method for the detection of antigen presenting cells
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
CA2214649C (en) * 1995-03-08 2007-06-12 Zeling Cai Antigen presenting system and methods for activation of t-cells
US5788963A (en) 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US5776487A (en) 1996-04-19 1998-07-07 Pasteur Sanofi Diagnostics Liposome reagents for immunoassays
US5780319A (en) 1996-04-19 1998-07-14 Pasteur Sanofi Diagnostics Immunoassays to detect antiphospholipid antibodies
ES2278390T3 (es) * 1996-05-23 2007-08-01 The Scripps Research Institute Sistema de presentacion de antigenos de clase ii de cmh y procedimientos de activacion de linfocitos t cd4+.
US5750356A (en) 1996-05-31 1998-05-12 Anergen, Inc. Method for monitoring T cell reactivity
US5834015A (en) 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same

Also Published As

Publication number Publication date
US7022483B1 (en) 2006-04-04
AU774442B2 (en) 2004-06-24
HK1041433A1 (zh) 2002-07-12
AU1129300A (en) 2000-05-08
DK1123086T3 (da) 2010-06-14
EP1123086B1 (de) 2010-03-03
WO2000023053A3 (en) 2000-11-23
CA2345277A1 (en) 2000-04-27
AU2004218655A1 (en) 2004-11-04
CA2345277C (en) 2011-05-24
DE69942100D1 (de) 2010-04-15
EP1123086A2 (de) 2001-08-16
JP2002527467A (ja) 2002-08-27
WO2000023053A2 (en) 2000-04-27

Similar Documents

Publication Publication Date Title
ATE459339T1 (de) Künstliche antigen-spezifischen zellen und zugehörige verfahren
WO2001094944A3 (en) Artificial antigen presenting cells and methods of use thereof
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
DE69435292D1 (de) Verfahren zur herstellung von immunogenen hla-a2.1-bindenden peptiden
BG103251A (bg) Оксадиазоли, методи за получаването им и приложението им като лекарствени средства
NO996358L (no) Systemer for landbasert kjoeretoeysdistribusjon avf lytende naturgass
EP0997477A3 (de) MHC-Komplexe und ihre Verwendung
ATE213068T1 (de) Testverfahren für peptidspezifische t-zellen
ATE219380T1 (de) Vehikel zum einbringen von nukleinsäuren in zellen
AU5898400A (en) Hla binding peptides and their uses
DE69334076D1 (de) Hla bindepeptide und ihre verwendungen
WO2003040165A3 (en) Hla class i and ii binding peptides and their uses
ATE394474T1 (de) Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen
DE69826452D1 (de) Stellenspezifische proteinmodifizierung
DE69632827D1 (de) Materialen und methoden im zusammenhang mit bindung und präsentation von substanzen auf zelloberflächen
DK0807178T3 (da) Mycobaktielle proteiner, mikroorganismer producerende samme og anvendelser af nævnte proteiner i vacciner og til påvisning af tuberkulose
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
DE69731836D1 (de) Induzierung von t zell toleranz unter verwendung eines löslichen moleküls, dass gleichzeitig zwei kostimulierungswege blockieren kann
CA2262001A1 (en) Mhc binding peptide oligomers and methods of use
DE69836999D1 (de) System zur Vorbereitung von Poststücken
AU4423799A (en) Methods and agents for modulating the immune response and inflammation involvingmonocyte and dendritic cell membrane proteins
AU6930200A (en) Use of lentiviral vectors for antigen presentation in dendritic cells
ATE191223T1 (de) Verwendung von zelladhäsions-peptiden zur modifikation des haftungsvermögens eukaryontischer zellen untereinander
AU7615900A (en) Isolated peptides which bind to mhc class ii molecules, and uses thereof
AU1457199A (en) Isolation, characterization, and identification of dendritic like cells and methods of using same

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties